“…In fact, this topic was largely investigated to minimize healthy tissue toxicity, focalizing the high dose to a smaller tumour volume. [27][28][29][30][31] Concerning lung RT, in a small series of 38 patients affected by unresectable NSCLC and treated with concomitant chemo-conventional RT, tumour volume response evaluated by means of weekly CBCT was associated with a longer OS. 17 Unfortunately, no measured CBCT cut-off tumour response was determined for a better understanding of the behaviour or prediction of therapeutic outcomes.…”